Levobetaxolol

Drug Profile

Levobetaxolol

Alternative Names: AL 1577; AL 1577A; Betaxon; Levobetaxolol hydrochloride

Latest Information Update: 22 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alcon
  • Class Antiglaucomas; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Glaucoma; Ocular hypertension

Most Recent Events

  • 16 Dec 2015 Withdrawn for Glaucoma and Ocular hypertension in USA (Ophthalmic) before December 2015
  • 26 Aug 2010 Alcon has been acquired by Novartis
  • 06 Mar 2002 First global launch of levobetaxolol in the US in 2001
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top